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Abstract
The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response
patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in comparison with RECIST1.1,
which constitutes an important step to further understand immune-related response phenomena. This commentary
discusses the key observations in the study in terms of their implications and pitfalls, and describes unmet needs that
remain to be addressed. The article also emphasizes the important role of tumor response criteria as a “common
language” to describe the results of cancer treatment, and discusses future directions for further advances of the field
of immuno-oncology.
Unconventional tumor response patterns associated with
immune-checkpoint blockade provide challenges for
evaluations of treatment benefits in patients treated with
immune-checkpoint inhibitors. In the recent JCO article
by Hodi et al., atypical response patterns were evaluated
using immune-related response criteria (irRC) by a
retrospective analysis of 327 melanoma patients treated
with PD-1 inhibitor pembrolizumab therapy [1]. This is
the first study that evaluated immune-related responses
in a large number of patients treated with PD-1 inhibitor
therapy and reported the overall survival data in correl-
ation with irRC and RECIST assessments. Their results
indicated that the conventional RECIST assessment
alone may underestimate the benefit of PD-1 inhibitor
therapy in a subset of patients, supporting a need of
immune-related response evaluation strategy that has
been increasingly recognized among investigators in
immuno-oncology community. The study has provided
important and insightful observations and presented
remaining and emerging challenges. Further discussions
of some of the key observations help to understand the
implications and pitfalls, and to develop strategies that
address the challenges. Of note, tumor response criteria
should serve as a “common language” to describe treat-
ment results and provide a basis for advances in cancer
therapy [2–4], and therefore the detailed methods of
evaluating and defining immune-related responses deserve
careful review to discuss the implications of the study on
further growth of immuno-oncology community.
Response patterns unique to immune-checkpoint in-
hibitor therapy can be noted i) after an initial increase
of tumor burden or ii) during or after the appearance
of new lesions [5–7]. The phenomena are termed
“pseudoprogression”, because they would be classified
as progressive disease (PD) by conventional RECIST
[5–9]. To capture these unconventional response pat-
terns, irRC was proposed in 2009 with the key features
including 1) requirement of confirmation of PD on
two consecutive scans at least 4 weeks apart, and 2)
inclusion of new lesion measurements to the total
tumor burden [5–7]. These criteria are distinct from
RECIST which immediately defines PD at tumor bur-
den increase above the threshold or at the appearance
of new lesions. While irRC is increasingly recognized,
most trials of immune-checkpoint inhibitors continue
to use RECIST1.1 to obtain standardized endpoints
used for regulatory approvals in the past decade.
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Moreover, regulatory authorities have not yet ac-
cepted immune-related response evaluations as an
endpoint for registrational studies. A need for in-
creased reporting of immune-related responses has
been recently acknowledged to address these issues
[10], leading to the important initiative by Hodi et al. in
their study [1].
irRC versus RECIST1.1: Methodological differences
and their implications
To discuss the results of immune-related responses in their
study, the methodological issues of immune-related re-
sponse evaluations need to be clarified. The original irRC
used in the study by Hodi et al. [1] was based on WHO cri-
teria and utilizes bidimensional measurements, quantifying
the tumor burden using a product of the longest diameter
and the longest perpendicular diameter [2]. On the other
hand, RECIST1.1 uses unidimensional measurements,
quantifying lesions with the longest diameters except for
lymph nodes that use short axis [9, 11]. This methodo-
logical difference is a challenge for a direct comparison
between irRC and RECIST1.1, because some differences in
response evaluations may be due to the difference between
unidimensional and bidimensional measures, and may not
be due to immune-related response phenomena. Although
their motives of comparing irRC against RECIST1.1 are
understandable, additional comparisons between irRC and
WHO criteria could have contributed to detect the differ-
ences purely due to immune-related response phenomena
captured by the novel features of irRC, as these two criteria
share the same measurement methods with identical
thresholds for response and progression.
Measurement variability is another important issue.
Multiple prior studies have demonstrated that unidi-
mensional measurements used in RECIST are associ-
ated with much less measurement variability compared
to bidimensional measurements in WHO/irRC, and
therefore can more accurately characterize small tumor
burden changes [12–14]. The concept of measurement
variability is directly relevant to the threshold values
that define response and progression. Notably, the
threshold of 25 % bidimensional increase for PD in
WHO/irRC can be within the measurement variability,
and thus may not necessarily indicate true tumor
increase [3, 7, 14]. A prior study by Erasmus et al.
reported 43 % misclassification rate for PD using WHO
criteria due to interobserver measurement variability
[14]. Moreover, smaller lesions are more vulnerable to
misclassification, because a small absolute difference in
measurements can results in a large percent change
[15]. The concept of measurement variability should be
carefully applied when interpreting the results of the
irRC assessments.
Pseudoprogression: Definitions, pitfalls, and unmet
needs
The study described two types of pseudoprogression; 1)
early pseudoprogression with ≥25 % increase at 12 weeks
that is not confirmed as PD at the next assessment, and 2)
delayed pseudoprogression with ≥25 % increase after
12 weeks that was not confirmed as PD at the next assess-
ment [1]. The observation is interesting because pseudo-
progression to date indicated “initial” tumor burden
increase followed by subsequent decrease, which mostly
falls into “early pseudoprogression”. Although it is intuitive
that pseudoprogression does not always occur within
12 weeks of therapy, their observations of delayed pseudo-
progression may need to be interpreted with caution in the
light of measurement variability. In the spiderplot of 9
delayed pseudoprogressors (Fig. 1B of the JCO article), 7
patients experienced tumor decrease before demon-
strating ≥25 % increase from the nadir, including 4
patients who achieved partial response with ≥50 % ini-
tial tumor decrease [1]. Subsequent tumor burden in-
crease was relatively small in these patients and right
around 25 % comparing to the nadir; this is most not-
able in a patient whose nadir before pseudoprogression
was around –90 % of baseline [1]. It is possible that
some cases of “delayed pseudoprogression” are due to
measurement variability rather than immune-related
response phenomenon. Certain degree of tumor burden
fluctuations due to measurement variability are noted
during any cancer therapy, particularly when evaluating
small tumor burden after initial response using bidi-
mensional measurements that are subject to large
variability.
Interestingly, the precise definitions of pseudoprogres-
sion have not been actively debated to date. The study
defined subsequent tumor reduction as “not confirmed
as PD at the next assessment”, and did not require
tumor reduction below the partial response threshold.
Although this may reflect the concept that “stable dis-
ease” is a pattern of response [6], requirement of certain
duration of stable disease is likely needed to more rigor-
ously define pseudoprogression. Precise definition will
also help to promote the consistent use of the term
“pseudoprogression” to describe the unique immune-
related phenomenon. Other terms such as “tumor flare”
or “disease flare” should be avoided as these terms have
been used to describe oncologic conditions that are un-
related to immune-checkpoint inhibitor therapy [16–18].
Another pitfall of the particular version of irRC used
in the study is “reset baseline”, which was not used in
WHO, RECIST, or in the original irRC; the original irRC
mentioned such concept yet defined PD in comparison
with nadir [6]. The original irRC commented on a
tendency in clinical practice to compare with the most
recent prior study when evaluating tumors, as a reason
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to consider “reset baseline” [6]. However, the serial evalu-
ation of tumor burden dynamics throughout the course of
therapy starting at baseline has been the foundation of
tumor response criteria over the past 3 decades, and its
importance is well-recognized in clinical investigations
and practice [19–21]. Indeed, experienced oncologists
often review several prior scans to capture the overall ten-
dency of tumor kinetics during therapy. Tumor response
criteria offer a unique opportunity to characterize tumor
dynamics according to the rigorous methods and stan-
dardized language, and baseline burden is a pivotal item
[2]. Introducing “reset baseline” without rigorous scientific
data supporting the approach has a potential to cause fur-
ther confusions of immune-related response evaluations
and navigate the community away from establishing a
consensus. The field currently suffers from a lack of con-
sistencies with the use of different “versions” of immune-
related response criteria in clinical trials. A consensus on
a unified strategy to effectively evaluate immune-related
responses is sorely needed.
Detailed descriptions of pseudoprogression certainly
constitute important advances in knowledge provided by
the study. There remain unmet clinical needs to be
addressed, including predictors and early markers of pseu-
doprogression that help to differentiate pseudoprogressors
and true progressors in earlier course of therapy to facilitate
treatment decisions.
Future directions
Important insights for future directions are provided
by Hodi et al., including the use of unidimensional
measurement and modifications of RECIST criteria
specific to immune-related response evaluations [1].
Such direction is reasonable given the widely accepted
use of RECIST in most trials in the past decade. A
prior study demonstrated that unidimensional irRC
provides highly concordant assessment compared to
bidimensional irRC with less measurement variability
[3]. Another study reported that modifications of uni-
dimensional irRC according to the revisions in
RECIST1.1 regarding the number of target lesions
and lymph node assessment also led to concordant
immune-related response evaluations [22]. These
studies have provided a basis for a direction toward
immune-related RECIST1.1 (irRECIST1.1), using uni-
dimensional measurements while maintaining the key
features of irRC including new lesion assessments and
confirmation for progression. Such approach provides
a measure for immune-related response evaluations
that allow for “head-to-head” comparisons with the
conventional RECIST [3, 7, 22]. The study by Hodi et
al. constitutes an important step for further endeavors
of immune-related evaluations, where the immune-
oncology community needs to bring multidisciplinary
expertise together to establish consensus, address un-
met needs, and advance the field.
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